Visualizing How to Use Antipsychotics for Agitated Delirium in the Last Days of Life

Delirium Motor Subtypes and Severity of Physical Symptoms in Patients with Advanced Cancer in Inpatient Hospice/Palliative Care Units: A Multicenter Prospective Cohort Study

Background: Altered cognitive function due to delirium changes the threshold or tolerance of symptoms. The impacts of delirium motor subtypes on symptoms remain unknown. Objectives: Determining whether delirium motor subtypes are associated with the severity of physical symptoms in a palliative care setting. Design: A secondary analysis of a multicenter prospective observational study. Setting/Subjects: We included consecutive patients with advanced cancer admitted to 23 inpatient hospices in Japan in 2017. Measurements: Occurrence of delirium, motor subtype, and severity of pain and dyspnea (Integrated Palliative Care Outcome Scale) were assessed at admission (T1) and on the day of Palliative Performance Scale declined to 20 (T2). Results: T1 and T2 data were obtained from 1896 and 1396 patients, respectively. Using patients without delirium as a reference, the odds ratio (OR) for moderate-to-overwhelming pain among those with hyperactive or mixed delirium was significantly higher at T1 and T2 (OR, 95% confidence interval [CI]: 1.49, 1.15-1.92, and 1.71, 1.26-2.32, respectively). A similar trend was observed for dyspnea at T1 and T2 (OR, 95% CI: 1.54, 1.16-2.06, and 1.88, 1.39-2.55, respectively). However, patients with hypoactive delirium did not have higher odds of developing severe symptoms. Patients without delirium at T1, who developed hyperactive or mixed delirium, had a higher severity of both pain and dyspnea than those who were delirium-free (OR, 95% CI; 1.60, 1.08-2.37, and 1.86, 1.27-2.72, respectively) at T2. Conclusion: Hyperactive delirium is associated with the intensity of pain and dyspnea in patients receiving palliative care.

Comparison of Pharmacological Treatments for Agitated Delirium in the Last Days of Life

CONTEXT

Antipsychotics are often used in managing symptoms of terminal delirium, but evidence is limited.

OBJECTIVES

To explore the comparative effectiveness of haloperidol with as-needed benzodiazepines (HPD) vs. chlorpromazine (CPZ) vs. levomepromazine (LPZ) for agitated delirium in the last days.

METHODS

A prospective observational study was conducted in two palliative care units in Japan. Adult cancer patients who developed agitated delirium with a modified Richmond Agitation-Sedation Scale (RASS-PAL) of one or more were included; palliative care specialist physicians determined that the etiology was irreversible; and estimated survival was 3 weeks or less. Patients treated with HPD, CPZ, or LPZ were analyzed. We measured RASS, NuDESC, Agitation Distress Scale (ADS), and Communication Capacity Scale (CCS) on Days 1 and 3.

RESULTS

A total of 277 patients were enrolled, and 214 were analyzed (112 in HPD, 50 in CPZ, and 52 in LPZ). In all groups, the mean RASS-PAL score significantly decreased on Day 3 (1.37 to -1.01, 1.87 to -1.04, 1.79 to -0.62, respectively; P < 0.001); the NuDESC and ADS scores also significantly decreased. The percentages of patients with moderate to severe agitation and those with full communication capacity on Day 3 were not significantly different. The treatments were well-tolerated. While one-fourth of HPD group changed antipsychotics, 88% or more of CPZ and LPZ groups continued the initial antipsychotics.

CONCLUSION

Haloperidol with as-needed benzodiazepine, chlorpromazine, or levomepromazine may be effective and safe for terminal agitation. Chlorpromazine and levomepromazine may have an advantage of no need to change medications.

Effectiveness of antipsychotics for managing agitated delirium in patients with advanced cancer: a secondary analysis of a multicenter prospective observational study in Japan (Phase-R)

PURPOSE

Delirium is a common and serious comorbidity in patients with advanced cancer, necessitating effective management. Nonetheless, effective drugs for managing agitated delirium in patients with advanced cancer remain unclear in real-world settings. Thus, the present study aimed to explore an effective pharmacotherapy for this condition.

METHODS

We conducted a secondary analysis of a multicenter prospective observational study in Japan. The analysis included patients with advanced cancer who presented with agitated delirium and received pharmacotherapy. Agitation was defined as a score of the Richmond Agitation-Sedation Scale for palliative care (RASS-PAL) of ≥ 1. The outcome was defined as -2 ≤ RASS-PAL ≤ 0 at 72 h after the initiation of pharmacotherapy. Multiple propensity scores were quantified using a multinomial logistic regression model, and adjusted odds ratios (ORs) were calculated for haloperidol, chlorpromazine, olanzapine, quetiapine, and risperidone.

RESULTS

The analysis included 271 patients with agitated delirium, and 87 (32%) showed -2 ≤ RASS-PAL ≤ 0 on day 3. The propensity score-adjusted OR of olanzapine was statistically significant (OR, 2.91; 95% confidence interval, 1.12 to 7.80; P = 0.030).

CONCLUSIONS

The findings suggest that olanzapine may effectively improve delirium agitation in patients with advanced cancer.